Olena Mozgova

Dr. Olena Mozgova


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Journal of Polymers and the Environment
Verified
Journal Article
Open access
PDF file
OMOlena Mozgova
Olena Mozgova
OCOlga Chernyayeva
Olga Chernyayeva
ASAnna Sroka-Bartnicka
Anna Sroka-Bartnicka
PPPiotr Pieta
Piotr Pieta
RNRobert Nowakowski
Robert Nowakowski
ISIzabela S.PIeta
Izabela S.PIeta
Biodegradable polymers and their diverse applications, particularly in the pharmaceutical and biomedical fields, have experienced significant advancements in recent decades. The importance of this research is underscored by the potential of biodegradable polymeric biomaterials to transform drug delivery systems, tissue engineering scaffolds, and a wide range of biomedical devices. This progress has been driven by the growing demand for sustainable and eco-friendly solutions across various sectors, including biomedicine, nanotechnology, the food industry, solar cells, and waste management. Central to this development is understanding the physical and chemical characteristics of biodegradable polymers, particularly their surface and interfacial properties, which profoundly impact their behavior and functionality. This review provides an overview of the physicochemical methods employed to investigate polymer surfaces, highlighting their complex applications and their role in defining the potential uses of newly synthesized polymers. Techniques such as X-ray photoelectron spectroscopy (XPS), diffuse reflectance infrared Fourier transform spectroscopy (DRIFT), and atomic force microscopy (AFM) are emphasized explicitly as essential tools for elucidating the intricate structure and properties of biodegradable polymers. A comprehensive understanding of the physicochemical structure, surface morphology, and composition of biodegradable polymers is crucial for designing materials with tailored properties and developing novel materials with specific, desired characteristics.

17 March 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
Barbara GierobaBarbara Gieroba
Barbara Gieroba
VVVladyslav Vivcharenko
Vladyslav Vivcharenko
GKGrzegorz Kalisz
Grzegorz Kalisz
PKPaulina Kazimierczak
Paulina Kazimierczak
OMOlena Mozgova
Olena Mozgova
ASAnna Sroka-Bartnicka
Anna Sroka-Bartnicka
Recent advances in modern medicine emphasize patient-centric and personalized therapeutic strategies, particularly for chronic and regenerative applications. Among emerging biomaterials, chitosan (CS) has gained considerable attention due to its biocompatibility, biodegradability, and antimicrobial properties, while its molecular weight strongly influences structural organization and interactions with active compounds. In this study, chitosan-based matrices—2% (w/v) low-molecular-weight CS, 4% (w/v) low-molecular-weight CS, and 2% (w/v) medium-molecular-weight CS—were developed and enriched with ibuprofen (IBU), a widely used non-steroidal anti-inflammatory drug, to improve topical delivery and reduce systemic side effects. The physicochemical properties of gelled thin films were investigated with emphasis on molecular arrangement, surface characteristics, and drug release behavior in phosphate-buffered saline. ATR-FTIR spectroscopy, contact angle measurements, and atomic force microscopy (AFM) were employed to evaluate structural and functional changes induced by IBU incorporation. Medium-molecular-weight CS exhibited lower water contact angles (≈69–73°) and higher surface free energy (≈41–44 mN m−1) compared to low-molecular-weight CS, while IBU loading did not significantly alter wettability. AFM analysis revealed drug-induced surface roughness changes, with Ra increasing from 23.9 nm (2CS_M) to 29.4 nm after IBU loading and further to 35.5 nm following release. ATR-FTIR spectra confirmed preservation of characteristic chitosan amide I and II bands (∼1645 and ∼1556 cm−1), with spectral changes in the 1450–1700 cm−1 region indicating interactions between IBU and CS functional groups. Among the investigated systems, 2% (w/v) medium-molecular-weight chitosan demonstrated the most favorable sustained IBU release (∼50% after 48 h), highlighting its potential for dermal drug delivery and personalized therapeutic applications.

5 January 2024 in Chemical Papers
Verified
Journal Article
Open access
PDF file
OMOlena Mozgova
Olena Mozgova
MBMykola Blazheyevskiy
Mykola Blazheyevskiy
LKLiubomyr Kryskiw
Liubomyr Kryskiw
TKTetyana Kucher
Tetyana Kucher
OSOksana Shliusar
Oksana Shliusar
VMValeriy Moroz
Valeriy Moroz
A new difference spectrophotometric method for the determination of prothipendyl hydrochloride in commercial pharmaceutical preparations has been proposed. The method includes oxidation of an aliquot of the drug solution with potassium caroate to form the corresponding sulfoxide (ε = (5.83 ± 0.07) × 103 L/mol cm) and subsequent measurement of the absorbance at 340 nm compared to that of the unoxidized drug solution of equal concentration. The graph of Beer’s law for prothipendyl hydrochloride shows that the ΔA values measured at the corresponding wavelength are proportional to the concentration of the drug in the concentration range of 1.5–70 µg/mL. The characteristics of the curve calibration curve of the linear regression equation were as follows: ΔA = (69.24 ± 1.78) × 10–4C (where C in μg/mL). A new spectrophotometric technique has been developed and the possibility of quantitative determination of prothipendyl hydrochloride monohydrate in Dominal® tablets of 40 mg has been demonstrated. RSD ≤ 1.3%; (│δ│ < tα × RSD/ $$\sqrt{n}$$ n ), where µ is quantification data given in the Certificate of Quality, δ = (x̅-µ) 100%/µ. The resulting difference in absorption does not depend on the presence of excipients and possible API oxidation products in the composition.

31 October 2022 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MBMykola Yevstahiyovich Blazheyevskiy
Mykola Yevstahiyovich Blazheyevskiy
DADeghinmotei Alfred-Ugbenbo
Deghinmotei Alfred-Ugbenbo
OMOlena Mozgova
Olena Mozgova
VMValery Petrovich Moroz
Valery Petrovich Moroz
Objectives: To develop two (titrimetric and spectrophotometric) simple, rapid, sensitive and cost-effective methods for the determination of metoclopramide (MCP) in pharmaceutical dosage forms.Materials and Methods: The titrimetric method (A) was based on the N-oxidation reaction involving the use of potassium hydrogen peroxymonosulfate and subsequent iodometric back titration of a known residual reagent. The spectrophotometric method (B) was based on derivatization of MCP with potassium hydrogen peroxymonosulfate in the presence of iodide to produce a chromogen (triiodide) with a wavelength of maximum absorption at 350 nm.Results: Method "A" was applicable over the concentration range of 0.25-3.5 mg to end volume 10 mL. In method "B", Beer's law was obeyed over the concentration range of 0.3-3.5 mu g/mL with molar absorptivity of 24600 L/mol cm. The limits of quantification were calculated to be 0.25 mg/10 mL (A) and 0.2 mu g/mL (B), respectively.Conclusion: The proposed methods were suitable for determination of MCP as a pure substance in tablets and injection.

18 June 2024 in Chemical Papers
Verified
Journal Article
Open access
PDF file
OMOlena Mozgova
Olena Mozgova
MBMykola Blazheyevskiy
Mykola Blazheyevskiy
LKLiubomyr Kryskiw
Liubomyr Kryskiw
TKTetyana Kucher
Tetyana Kucher
OSOksana Shliusar
Oksana Shliusar
VMValeriy Moroz
Valeriy Moroz
Metopimazine (MPZ) is a dopamine antagonist from the phenothiazine class of drugs. It has antiemetic properties and is used to treat nausea and vomiting, including those associated with cancer chemotherapy. We have proposed a new method for the quantitative determination of Metopimazine by spectrophotometry. The drug is determined using a difference spectrophotometric technique based on the absorbance of its previously prepared sulfoxide derivative (λmax = 355 nm, ε = 4.5 × 103 L/mol cm) relative to a solution of a non-derivatised drug. The sulfoxide derivative is formed quickly and quantitatively at room temperature by adding potassium caroate solution. The difference in the absorbance of solutions at 355 nm is proportional to the concentration of MPZ in the drug. The method is specific for an intact drug in the presence of oxidative and photochemical decomposition products and excipients. The linearity range is 0.9–30.0 μg/mL. Regression line equation: ΔA = 0.0061 × c (r = 0.999), where c is the MPZ concentration in μg/mL. The limit of quantitation, LOQ (10S), is 2.8 μg/mL. The possibility of quantitative determination of MPZ content in the bulk drug and tablets of Vogalen Lyok 7.5 mg with a relative standard deviation of 1.21% (δ = + 0.05%) and 1.38% (δ = – 0.67%), respectively, was shown. │δ│ < tα (0.95, n = 7) × RSD/√n, where δ = ( $$\overline{x}$$ x ¯ –μ) × 100%/μ (μ—quantification data, given in the Certificate of Quality).

21 December 2016 in News of Pharmacy
Verified
Journal Article
Open access
PDF file
MBMykola Yevstahiyovich Blazheyevskiy
Mykola Yevstahiyovich Blazheyevskiy
OMOlena Mozgova
Olena Mozgova
The quantitative determination of hydrogen peroxide by voltammetry on the carbositall electrode